These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 12823492)

  • 1. Pramipexole and pergolide in the treatment of depression in Parkinson's disease: a national multicentre prospective randomized study.
    Rektorová I; Rektor I; Bares M; Dostál V; Ehler E; Fanfrdlová Z; Fiedler J; Klajblová H; Kulist'ák P; Ressner P; Svátová J; Urbánek K; Velísková J
    Eur J Neurol; 2003 Jul; 10(4):399-406. PubMed ID: 12823492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Double-blind, single-dose, cross-over study of the effects of pramipexole, pergolide, and placebo on rest tremor and UPDRS part III in Parkinson's disease.
    Navan P; Findley LJ; Jeffs JA; Pearce RK; Bain PG
    Mov Disord; 2003 Feb; 18(2):176-80. PubMed ID: 12539211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy, safety, and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson's disease: a double blind, placebo controlled, randomised, multicentre study.
    Pinter MM; Pogarell O; Oertel WH
    J Neurol Neurosurg Psychiatry; 1999 Apr; 66(4):436-41. PubMed ID: 10201413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.
    Parkinson Study Group
    JAMA; 2000 Oct; 284(15):1931-8. PubMed ID: 11035889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
    Barone P; Poewe W; Albrecht S; Debieuvre C; Massey D; Rascol O; Tolosa E; Weintraub D
    Lancet Neurol; 2010 Jun; 9(6):573-80. PubMed ID: 20452823
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Switching from pergolide to pramipexole in patients with Parkinson's disease.
    Hanna PA; Ratkos L; Ondo WG; Jankovic J
    J Neural Transm (Vienna); 2001; 108(1):63-70. PubMed ID: 11261747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The long-lasting improvement of sexual dysfunction in patients with advanced, fluctuating Parkinson's disease induced by pergolide: evidence from the results of an open, prospective, one-year trial.
    Pohanka M; Kanovský P; Bares M; Pulkrábek J; Rektor I
    Parkinsonism Relat Disord; 2005 Dec; 11(8):509-12. PubMed ID: 15994112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized, double-blind, 3-month parallel study of the effects of pramipexole, pergolide, and placebo on Parkinsonian tremor.
    Navan P; Findley LJ; Jeffs JA; Pearce RK; Bain PG
    Mov Disord; 2003 Nov; 18(11):1324-31. PubMed ID: 14639675
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An open-label, multicentre clinical trial to determine the levodopa dose-sparing capacity of pramipexole in patients with idiopathic Parkinson's disease.
    Pinter MM; Rutgers AW; Hebenstreit E
    J Neural Transm (Vienna); 2000; 107(11):1307-23. PubMed ID: 11145006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomly assigned double-blind cross-over study examining the relative anti-parkinsonian tremor effects of pramipexole and pergolide.
    Navan P; Findley LJ; Undy MB; Pearce RK; Bain PG
    Eur J Neurol; 2005 Jan; 12(1):1-8. PubMed ID: 15613140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cognitive performance in people with Parkinson's disease and mild or moderate depression: effects of dopamine agonists in an add-on to L-dopa therapy.
    Rektorová I; Rektor I; Bares M; Dostál V; Ehler E; Fanfrdlová Z; Fiedler J; Klajblová H; Kulist'ák P; Ressner P; Svátová J; Urbánek K; Velísková J
    Eur J Neurol; 2005 Jan; 12(1):9-15. PubMed ID: 15613141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of pramipexole in early Parkinson disease. A randomized dose-ranging study. Parkinson Study Group.
    JAMA; 1997 Jul; 278(2):125-30. PubMed ID: 9214527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease. International Pramipexole-Bromocriptine Study Group.
    Guttman M
    Neurology; 1997 Oct; 49(4):1060-5. PubMed ID: 9339690
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term efficacy and safety of pramipexole in advanced Parkinson's disease: results from a European multicenter trial.
    Möller JC; Oertel WH; Köster J; Pezzoli G; Provinciali L
    Mov Disord; 2005 May; 20(5):602-10. PubMed ID: 15726540
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pramipexole in Parkinson disease. Results of a treatment observation].
    Reichmann H; Brecht HM; Kraus PH; Lemke MR
    Nervenarzt; 2002 Aug; 73(8):745-50. PubMed ID: 12242961
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conversion from dopamine agonists to pramipexole. An open-label trial in 227 patients with advanced Parkinson's disease.
    Linazasoro G;
    J Neurol; 2004 Mar; 251(3):335-9. PubMed ID: 15015015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anhedonia, depression, and motor functioning in Parkinson's disease during treatment with pramipexole.
    Lemke MR; Brecht HM; Koester J; Kraus PH; Reichmann H
    J Neuropsychiatry Clin Neurosci; 2005; 17(2):214-20. PubMed ID: 15939976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pramipexole. A review of its use in the management of early and advanced Parkinson's disease.
    Dooley M; Markham A
    Drugs Aging; 1998 Jun; 12(6):495-514. PubMed ID: 9638397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pramipexole versus sertraline in the treatment of depression in Parkinson's disease: a national multicenter parallel-group randomized study.
    Barone P; Scarzella L; Marconi R; Antonini A; Morgante L; Bracco F; Zappia M; Musch B;
    J Neurol; 2006 May; 253(5):601-7. PubMed ID: 16607468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of pramipexole, a novel dopamine (DA) agonist, in advanced Parkinson's disease.
    Molho ES; Factor SA; Weiner WJ; Sanchez-Ramos JR; Singer C; Shulman L; Brown D; Sheldon C
    J Neural Transm Suppl; 1995; 45():225-30. PubMed ID: 8748629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.